Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease

Stopped early · Phase 1

Conditions studied: Sickle Cell Disease

In brief

Propanolol is a beta blocker which has been found to inhibit the ability of epinephrine to upregulate sickle red cell adhesion to laminin and endothelial cells in vitro. The purpose of this pilot study is to administer one dose of propanolol to children with sickle cell disease and to measure pre and post dose red cell adhesion. The hypothesis is that a single dose of propanolol will decrease red cell adhesion to laminin and endothelial cells as compared to baseline.

Key facts

Study ID

NCT02012777

Run by

University of Miami

People needed

9

Starts

2010-06-01

Expected to finish

2013-04-03

Last updated by the study team

2017-06-08

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis of HbSS or HbSBeta0Thal
• age 10-17 years
• Weight 30kg or greater
• Hb 7mg/dL or greater
• informed consent

You may not qualify if…

• History of vaso-occlusive crisis during the past 6 weeks, or history of transfusion during the past 3 months.
• pregnancy
• history of heart failure, myocardial infarction, asthma, bradyarrythmias, hypotension, thyroid disease, diabetes, renal insufficiency
• concurrent medications: any antihypertensive medication, diuretics, thyroid replacement medications, any arrythmia medication, insulin, hypoglycaemic medication
• history of allergy to sulfonamides
• elevated BUN or creatinine

Where it is running

• University of Miami — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.